Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Gives Thumbs Down to Simponi--For Now

This article was originally published in The Pink Sheet Daily

Executive Summary

The controversial health technology assessment agency is unconvinced of the drug's cost benefit in a crowded market, which is already well served, and concerned about its long-term safety profile.
Advertisement

Related Content

With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
With Discount In Place, NICE Gives Nod To Amgen's Nplate For Bleeding Disorder
Evidence Insufficient To Compare Psoriatic Arthritis Drugs – AHRQ
Evidence Insufficient To Compare Psoriatic Arthritis Drugs – AHRQ
Schering/J&J's Simponi Gets Positive EU Nod For Approval; J&J Seeks Full Rights To Drug
Schering/J&J's Simponi Gets Positive EU Nod For Approval; J&J Seeks Full Rights To Drug
J&J Celebrates Simponi Approval With Schering – For Now

Topics

Advertisement
UsernamePublicRestriction

Register

PS071405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel